Dr. Marlow Hernandez - 01 Dec 2021 Form 4 Insider Report for Cano Health, Inc.

Role: CEO and President, Director
Signature: /s/ David J. Armstrong, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Dec 2021
Net transactions value: +$187,637
Form type: 4
Filing time: 06 Dec 2021, 15:05:17 UTC
Previous filing: 01 Dec 2021
Next filing: 07 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CANO	Class A Common Stock	Purchase	$109,375	+12,500	+0.44%	$8.75^*	2,876,962	03 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CANO	Warrants to purchase Class A Common Stock	Purchase	$25,900	+10,000	+2.3%	$2.59^*	436,469	01 Dec 2021	Class A Common Stock	10,000	$11.50	Direct
transaction	CANO	Warrants to purchase Class A Common Stock	Purchase	$52,362	+22,001	+5%	$2.38^*	458,470	03 Dec 2021	Class A Common Stock	22,001	$11.50	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $2.20 to $2.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(2) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $2.20 to $2.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1)-(2) to this Form 4.